Cost–Utility of First-Line Actinic Keratosis Treatments in Finland

Advances in Therapy

Volumn 32, Issue 5, 2015, Pages 455-476

  Soini, Erkki J ^a   Hallinen, Taru ^a   Sokka, Anna Leena ^b   Saarinen, Kari ^c  

^a Esior Oy   (Finland)

^b Leo Pharma Oy   (Finland)

^c PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

Actinic keratosis; Cost effectiveness; Cryosurgery; Diclofenac; Economic evaluation; Imiquimod; Ingenol mebutate; Modeling; Photodynamic therapy; Solar keratosis

Indexed keywords

AMINOLEVULINIC ACID; DICLOFENAC; IMIQUIMOD; INGENOL MEBUTATE; 3-INGENYL ANGELATE; DERMATOLOGICAL AGENT; DITERPENE;

ACTINIC KERATOSIS; AGE DISTRIBUTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CRYOSURGERY; DECISION TREE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FINLAND; HEALTH CARE COST; META ANALYSIS (TOPIC); PHARMACEUTICAL CARE; PHOTODYNAMIC THERAPY; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; REIMBURSEMENT; SECONDARY HEALTH CARE; TOPICAL TREATMENT; TREATMENT INDICATION; TREATMENT RESPONSE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; KERATOSIS, ACTINIC; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; DITERPENES; FINLAND; HEALTH CARE COSTS; HUMANS; KERATOSIS, ACTINIC; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84929879990     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0211-7     Document Type: Article

References (115)

1. Weinstock MA, Lee KC, Chren MM, Marcolivio K, VATTC Trial Group. Quality of life in the actinic neoplasia syndrome: the VA topical tretinoin chemoprevention (VATTC) trial. J Am Acad Dermatol. 2009;61:207–15.
2. Stockfleth E, Terhorst D, Braathen L, et al. Guideline on actinic keratoses. Berlin: European Dermatology Forum; 2010.
3. Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics. 2010;28:1055–64.
4. Pflugfelder A, Welter AK, Leiter U, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2012;26:48–53.
5. Bernard P, Dupuy A, Sasco A, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey. Dermatology. 2008;216:194–9.
6. Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009;27:451–64.
7. Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:39–44.
8. Perera E, McGuigan S, Sinclair R. Cost for the treatment of actinic keratosis on the rise in Australia. Version 2. F1000Res. 2014;3:184 (revised 2014 Aug 20).
9. Pitkänen S, Jeskanen L, Ylitalo L. Basalioomat, okasolusyöpä ja sen esiasteet, miten hoidan? [Basal cell carcinoma, squamous cell carcinoma and premalignant skin lesions—how to treat?]. Duodecim. 2014;130:643–53.
10. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998;139:1033–9.
11. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154–9.
12. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4–7.
13. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649–55.
14. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131:455–64.
15. Kivisaari A, Kähäri VM. Miten tunnistan ja hoidan aurinkokeratoosin [Diagnosis and treatment of actinic keratosis.]. Finn Med J. 2014;69:1321–4.
16. Green A. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol. 1992;1:47–51.
17. Lansbury L, Leonardi-Bee J, Perkins W, Goodacre T, Tweed JA, Bath-Hextall FJ. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010;(4):CD007869.
18. Finnish Cancer Registry. Cancer in Finland 2008 and 2009. Cancer Statistics of the National Institute for Health and Welfare (THL). Helsinki: Cancer Society of Finland; 2011.
19. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425–9.
20. Tinghög G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol. 2008;88:467–73.
21. Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40:505–15.
22. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375:673–85.
23. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;9(1):795–7.
24. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997;36:650–3.
25. Lober BA, Lober CW, Accola J. Actinic keratosis is squamous cell carcinoma. J Am Acad Dermatol. 2000;43(5 Pt 1):881–2.
26. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):8–10.
27. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22:189–96.
28. Berman B, Bienstock L, Kuritzky L, et al. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006;55(suppl):1–8.
29. Quatresooz P, Piérard-Franchimont C, Paquet P, Hubert P, Delvenne P, Piérard GE. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol. 2008;18:6–10.
30. Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008;18:651–9.
31. Feldman SR, Fleischer AB Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87:201–7.
32. Ko CJ. Actinic keratosis: facts and controversies. Clin Dermatol. 2010;28:249–53.
33. Airola K, Virolainen S, Saksela O. Ihon premalignit keratinosyyttimuutokset—etiologia, kliininen kuva ja hoito [Premalignant keratoses—aetiology, clinical picture and therapy.]. Finn Med J. 2004;59:4981–4.
34. Laukkanen A, Rummukainen J, Kivinen P, Lappalainen K. Ihon okasolusyöpä ja sen esiasteet. Duodecim. 2005;121:71–9.
35. Kotimäki J. Fotodynaaminen hoito on merkittävä vaihtoehto useissa pään ja kaulan alueen ihosyövissä. Finn Med J. 2009;64:3095–100.
36. Peltonen S, Kähäri VM. Ihotautien muuttuvat haasteet. Erikoislääkäri. 2012;22:163–6.
37. Hannuksela-Svahn A. Aktiininen keratoosi eli aurinkokeratoosi. [Actinic keratosis aka solar keratosis.] Lääkärikirja Duodecim; 2014.
38. Trakatelli M, Siskou S, Proby C, et al. The patient journey: a report of skin cancer care across Europe. Br J Dermatol. 2012;167(Suppl 2):43–52.
39. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934–43.
40. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase Iia study. Australas J Dermatol. 2009;50:16–22.
41. Schmieder G. Multicenter, open-label, dose-area escalation, cohort study to evaluate the safety and tolerability of PEP005 (ingenol mebutate) gel 0.05% applied for two consecutive days to treatment area(s) of up to a total of 100 cm2 in patients with actinic keratoses. J Am Acad Dermatol. 2010;62:AB106.
42. Anderson L. Multicenter, randomized, parallel-group, double-blind, vehicle-controlled phase III study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05%, in patients with actinic keratoses on non-head locations. In: 22nd congress of dermatology; 2011: Abstract P2180.
43. Berman B. A multicenter, randomized, parallel-group, double-blind, vehicle-controlled evaluation of the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015%, in patients with actinic keratoses on the head (face or scalp). In: 22nd World Congress of Dermatology; 2011: Abstract P2179.
44. Lebwohl M. A randomized, parallel-group, double-blind, vehicle-controlled, multicenter study of the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015%, in patients with actinic keratoses on the head. In: 22nd World Congress of Dermatology; 2011: Abstract P2181.
45. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.
46. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666–70.
47. Anderson L, Jarratt M, Schmieder G, Shumack S, Katsamas J, Welburn P. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100 cm(2) on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol. 2014;7:19–29.
48. Bettencourt MS. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. J Drugs Dermatol. 2014;13:269–73.
49. Goldenberg G, Berman B. Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis. Clin Cosmet Investig Dermatol. 2014;8:1–8.
50. Longo C, Neri L, Argenziano G, et al. Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases. J Eur Acad Dermatol Venereol. 2014. doi:10.1111/jdv.12714.
51. Lääkkeiden hintalautakunta. Terveystaloudellisen selvityksen laatiminen lääkevalmisteen korvattavuus- ja tukkuhintahakemukseen. Helsinki: Lääkkeiden hintalautakunta; 2014.
52. Behmane D, Lambot K, Irs A, Steikunas N. Baltic guideline for economic evaluation of pharmaceuticals (pharmacoeconomic analysis). 2002. Available from: http://www.ispor.org/peguidelines/source/Baltic-PE-guideline.pdf
53. Collège des Économistes de la Santé. French guidelines for the economic evaluation of health care technologies. Paris: CES; 2004.
54. College voor zorgverzekeringen. Guidelines for pharmacoeconomic research, updated version. Diemen: College voor zorgverzekeringen; 2006.
55. IPF Institut für Pharmaökonomische Forschung. Guidelines on Health Economic Evaluation. Vienna: IPF; 2006.
56. Scottish Medicines Consortium. Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). SMC; 2007.
57. Health Information and Quality Authority. Guidelines for the Economic Evaluation of Health Technologies in Ireland. HIQA; 2010.
58. López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11:513–20.
59. Belgian Health Care Knowledge Centre. Belgian guidelines for economic evaluations and budget impact analyses. 2nd ed. Brussels: KCE; 2012.
60. Norwegian Medicines Agency (Statens legemiddelverk). Guidelines on how to conduct pharmacoeconomic analyses. NOMA; 2012.
61. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. NICE; 2013.
62. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis. 2012;89:241–50.
63. ®). Glasgow: SMC; 2013.
64. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47:258–62.
65. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14:99–106.
66. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006;155:1029–36.
67. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratosis postcryosurgery. J Drugs Dermatol. 2008;7:669–73.
68. Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008;158:994–9.
69. Hauschild A, Popp G, Stockfleth E, et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol. 2009;18:116–21.
70. Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160:1066–74.
71. Huyke C, Reuter J, Rödig M, et al. Therapie von aktinischen Keratosen mit einem neuen Betulin-basierten Oleogel; eine prospektive, randomisierte, vergleichende Pilotstudie. Treatment of actinic keratoses with a novel botulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges. 2009;7:128–33.
72. McEwan LE, Smith JG. Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol. 1997;38:187–9.
73. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709–13.
74. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94–100.
75. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44:40–3.
76. Kose O, Koc E, Erbil AH, Caliskan E, Kurumlu Z. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat. 2008;19:159–63.
77. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62:573–81.
78. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582–90.
79. Chen K, Yap LM, Marks R, Shumack S. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol. 2003;44:250–5.
80. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714–21.
81. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51:547–55.
82. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141:467–73.
83. Ooi T, Barnetson RS, Zhuang L, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol. 2006;154:72–8.
84. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133–41.
85. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a keratoses, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157(Suppl 2):25–31.
86. Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol. 2009;161:897–903.
87. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227–32.
88. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85:424–8.
89. Pariser D, Loss R, Jarratt M, et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2008;59:569–76.
90. Braathen LR, Paredes BE, Saksela O, et al. Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol. 2009;23:550–5.
91. Szeimies RM, Matheson RT, Davis SA, et al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg. 2009;35:586–92.
92. Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813–6.
93. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5:133–9.
94. Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265–8.
95. Saarni SI, Härkänen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15:1403–14.
96. Ludwig MW, Oliveira Mda S, Muller MC, Moraes JF. Quality of life and site of the lesion in dermatological patients. An Bras Dermatol. 2009;84:143–50.
97. Suomen virallinen tilasto (SVT): Julkisten menojen hintaindeksi [verkkojulkaisu]. [Index for communal services]. Helsinki: Tilastokeskus; 2014.
98. Hallinen T, Soini EJ. The impact of the pharmaceutical pricing system on cost-effectiveness results: Finnish analysis. Open Pharmacoeconomics Health Econ J. 2011;3:6–10.
99. Kapiainen S, Väisänen A, Haula T. Terveyden-ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2011. [Health and social care unit costs in Finland in year 2011.] Tampere: Terveyden ja hyvinvoinnin laitos; 2014.
100. Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006. [Health care unit costs in Finland in year 2006.] Helsinki: Stakes; 2008.
101. Suomen virallinen tilasto (SVT): Kuluttajahintaindeksi [verkkojulkaisu]. [Consumer price index]. Helsinki: Tilastokeskus; 2014.
102. Tilastokeskus. Työvoimatutkimus. [Labor force survey]. Helsinki: Tilastokeskus; 2011.
103. Suomen virallinen tilasto (SVT): Ansiotasoindeksi [verkkojulkaisu]. [Income index]. Helsinki: Tilastokeskus; 2014.
104. Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. 2014;9:e96829.
105. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70(2 Suppl):30–6.
106. Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 2004;22:83–94.
107. Caekelbergh K, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol. 2006;155:784–90.
108. Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006;32:1045–9.
109. Annemans L, Caekelbergh K, Roelandts R, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol. 2008;18:539–46.
110. Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol. 2008;7:23–5.
111. Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat. 2009;20:266–75.
112. Colombo GL, Chimenti S, Di Matteo S, et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. G Ital Dermatol Venereol. 2010;145:573–81.
113. Wilson E, et al. Economic evaluations based on decision models: a response to Muston et al. J Dermatolog Treat. 2011;22:298–301.
114. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis. 1999;58(Suppl 1):I82–5.
115. Santaguida PL, Helfand M, Raina P. Challenges in systematic reviews that evaluate drug efficacy or effectiveness. Ann Intern Med. 2005;142(12 Pt 2):1066–72.